Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.
about
Targeting heat shock proteins to modulate α-synuclein toxicityProtein degradation pathways in Parkinson's disease: curse or blessingDirect visualization of CHIP-mediated degradation of alpha-synuclein in vivo: implications for PD therapeuticsSynthesis of 19-substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90Synthesis of macrolactam analogues of radicicol and their binding to heat shock protein Hsp90Distinct roles of molecular chaperones HSP90α and HSP90β in the biogenesis of KCNQ4 channelsChronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell lossHeat shock protein responses to aging and proteotoxicity in the olfactory bulb.Heat shock proteins in neurodegenerative disorders and agingMolecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathiesUbiquitinylation of α-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5).Gene therapy with mitochondrial heat shock protein 70 suppresses visual loss and optic atrophy in experimental autoimmune encephalomyelitis.Anti-inflammatory peptide regulates the supply of heat shock protein 70 monomers: implications for aging and age-related diseaseHeat shock protein defenses in the neocortex and allocortex of the telencephalon.Molecular chaperones in Parkinson's disease--present and futureInvolvement of Bcl-2-associated athanogene (BAG)-family proteins in the neuroprotection by rasagiline.A Rapid, Semi-Quantitative Assay to Screen for Modulators of Alpha-Synuclein Oligomerization Ex vivo.α-Synuclein oligomers and clinical implications for Parkinson disease.Gene therapy for misfolding protein diseases of the central nervous system.Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.Super Spy variants implicate flexibility in chaperone action.Identification of chaperones in a MPP+-induced and ATRA/TPA-differentiated SH-SY5Y cell PD model.Proteomic profiling of mitochondria: what does it tell us about the ageing brain?Adaptation and sensitization to proteotoxic stress.BAG5 Interacts with DJ-1 and Inhibits the Neuroprotective Effects of DJ-1 to Combat Mitochondrial Oxidative Damage.Molecular chaperones as therapeutic targets to counteract proteostasis defects.Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond.Hsp70 protein complexes as drug targets.The role of amyloidogenic protein oligomerization in neurodegenerative disease.Opportunities and challenges for molecular chaperone modulation to treat protein-conformational brain diseasesInvestigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.Discovery of the neuroprotective effects of alvespimycin by computational prioritization of potential anti-Parkinson agents.Chaperone-Based Therapies for Disease Modification in Parkinson's Disease.BAG3 facilitates the clearance of endogenous tau in primary neurons.An improved route to 19-substituted geldanamycins as novel Hsp90 inhibitors--potential therapeutics in cancer and neurodegeneration.Silencing of Hsp90 chaperone expression protects against 6-hydroxydopamine toxicity in PC12 cells.Alpha-synuclein oligomers: a new hope.N-Acetyl-l-Cysteine Protects Astrocytes against Proteotoxicity without Recourse to Glutathione.Impact of aging on heat shock protein expression in the substantia nigra and striatum of the female rat.The contribution of mutant GBA to the development of Parkinson disease in Drosophila.
P2860
Q26827066-15B306B1-553F-4E6A-9615-150087CC827BQ27026029-9497CA61-46F5-4274-B69E-AD504B315729Q27314815-44FD4149-6868-4391-9B94-7A7AA0769610Q27676888-D9494F78-6FEC-4F3F-A248-1D8F1C894DFEQ27688922-9EC0D594-1819-4610-B91E-E5B2567D3B24Q28115218-64BF20A1-2B4F-4871-8509-F9AE5998FBCAQ28538890-2BE14511-6E39-4DF5-BB23-5BBC988E89E5Q30382422-F7ECE472-3E8E-42A9-AFF2-D8DA2DB1311BQ30414556-6B919C61-C76B-495B-91E3-A7EE7D0CDCDCQ33715640-4CD821F9-371F-44C5-AC85-5CF3E9FFF494Q33831775-3F908865-3E7E-49BA-869B-4CE0746FA9D9Q34069978-C73B96EF-E5FA-4A4A-A842-DA57C18E830BQ35485951-7C4DEABD-9502-4F44-9104-C04860493710Q35561538-BB09B919-79BE-4A8C-820F-B326BA58F5DDQ35688796-5716258E-9587-4655-B589-F77A3D7B8829Q36411750-B1B1A010-D463-4B40-A768-23559A8A7DC9Q36475337-30CDE874-FF19-4F20-AE9D-2DBDACF40B84Q36718306-ECFC6052-3F0A-4C03-BCF5-FDBA04F80BD6Q36983203-974B1D14-50EF-4DDE-864C-7C73306B27ADQ37506492-D10EAF40-5C30-4F48-94F2-BD9A85E5AE38Q37542104-0033EF81-4FA6-4A04-9272-B112A9D21B3FQ37553863-D43DB3D2-F017-4A62-95F4-7826E285D32FQ37610171-DBB50C4D-3522-468A-872B-AC02A6D00BCEQ37651678-DD1407CF-6065-4147-A4EE-730E948F73BEQ37703450-93CBB307-517E-40C0-9AE9-EFE16C5826B1Q37880729-D36F69DE-C712-4664-A307-37B0CFE0B377Q37880734-74FF67DB-BDE0-4379-A16F-003DC3C2B589Q38037745-565AA960-F400-4951-AEFD-BD9A32BA2A08Q38093118-F1C4BD79-7FAE-4E14-9A6A-89AE5B92037DQ38093796-3DCBBE98-F365-4068-9B24-788643A30761Q38817063-E0F10FC2-FE43-4801-B07A-C84F0F1AF39CQ39048969-2F026635-0BD9-4FC0-93FF-C5D889CCCEC9Q41623081-AE480DE0-8BDE-4C1F-9D08-EE7427501BBBQ41813298-0C096A23-9C26-4264-9725-870A91C2EB2BQ42875861-37E43B24-938A-4C7E-A85D-67355494494BQ45813546-D499C7C8-7546-4985-AE3C-0FA250197296Q46321755-1F373F80-273B-45F7-848D-8A8DA7D1D6F7Q47919698-36F765AF-88AB-450D-862D-69CD65866A6FQ51147143-88FA34C5-5107-4857-9792-519FFAFA96BDQ52848620-438E3B18-DD81-491F-957F-17018D69BE6B
P2860
Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.
@en
Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.
@nl
type
label
Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.
@en
Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.
@nl
prefLabel
Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.
@en
Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.
@nl
P2093
P2860
P1476
Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.
@en
P2093
P2860
P304
P356
10.2174/187152710793237386
P577
2010-12-01T00:00:00Z